Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.33Last Year’s EPS
0.32Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 6.24%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for DexCom, with strong revenue growth, significant customer base expansion, and successful international market performance. However, challenges such as gross margin decline and operating income reduction were noted, indicating areas for improvement.Company Guidance
In the earnings call for DexCom, Inc.'s fiscal year 2024, the company reported an 8% organic revenue growth for the fourth quarter compared to the same period in 2023, resulting in a full-year organic revenue growth of 12%. DexCom ended 2024 with over 2.8 million global customers, a 25% increase from the previous year. The company experienced notable progress in expanding its U.S. prescriber base by more than 50,000 and improving sales force productivity. International revenue grew by 17% to $311 million in Q4, with notable coverage wins in key markets like France and New Zealand. DexCom's guidance for 2025 anticipates a total revenue of $4.6 billion, representing a 14% growth, driven by continued strong category growth, new product launches, and expanded coverage for the Stella product, which contributed to 2-3% of revenue. The company also expects improvements in gross profit margins, targeting 64-65%, and adjusted EBITDA of approximately 30% for the year.Strong Revenue Growth
DexCom reported fourth quarter organic revenue growth of 8% compared to Q4 2023, with full-year organic revenue growth of 12%.
Customer Base Expansion
Ended 2024 with more than 2.8 million customers globally, representing a 25% increase compared to 2023.
Significant Coverage Expansion
Gained coverage for over five million people with type 2 diabetes not on insulin in the US, with two of the three largest PBMs now covering DexCom CGM for anyone with diabetes.
International Market Success
International revenue grew 17% in Q4, with significant demand in France and New Zealand following coverage expansions.
Stella Over-the-Counter Product Success
More than 140,000 people used Stella in the first four months of its launch, with strong demand across various populations.
---
DXCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DXCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $84.09 | $89.07 | +5.92% |
| Oct 24, 2024 | $74.85 | $73.44 | -1.88% |
| Jul 25, 2024 | $107.85 | $64.00 | -40.66% |
| Apr 25, 2024 | $138.01 | $124.34 | -9.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Dexcom (DXCM) report earnings?
Dexcom (DXCM) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Dexcom (DXCM) earnings time?
Dexcom (DXCM) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DXCM EPS forecast?
DXCM EPS forecast for the fiscal quarter 2025 (Q1) is 0.33.
---
